Inactief instrument

Andere talen Zalicus Inc Nasdaq

Aandelen

US98887C1053

slotkoers Nasdaq Andere beurzen
- ^USD	-

2016	Transcript : EPIRUS Biopharmaceuticals, Inc., Q4 2015 Earnings Call, Mar 15, 2016
2015	Transcript : EPIRUS Biopharmaceuticals, Inc., Q3 2015 Earnings Call, Nov 16, 2015

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Motion for Asset Sale Approved for EPIRUS Biopharmaceuticals, Inc.	09-10-18
Praxis Precision Medicines, Inc. completed the acquisition of Z944 assets from EPIRUS Biopharmaceuticals, Inc. (OTCPK:EPRS.Q).	31-01-18
Motion for Asset Sale Approved for EPIRUS Biopharmaceuticals, Inc.	19-01-18
Praxis Precision Medicines, Inc. agreed to acquire Z944 assets from EPIRUS Biopharmaceuticals, Inc. (OTCPK:EPRS.Q) for $1 million.	18-01-18
Notice of Intent of Asset Sale Filed by EPIRUS Biopharmaceuticals, Inc.	11-12-17
Motion for Asset Sale Approved for EPIRUS Biopharmaceuticals, Inc.	19-09-16
EPIRUS Biopharmaceuticals, Inc.(OTCPK:EPRS.Q) dropped from S&P TMI Index	05-08-16
EPIRUS Biopharmaceuticals, Inc.(OTCPK:EPRS.Q) dropped from NASDAQ Composite Index	03-08-16
EPIRUS Biopharmaceuticals, Inc. Announces Management Resignations	25-07-16
EPIRUS Biopharmaceuticals, Inc. Filed for Bankruptcy	25-07-16
EPIRUS Biopharmaceuticals, Inc. Announces Executive Termination	01-07-16
Polpharma S.A. completed the acquisition of EPIRUS Biopharmaceuticals (Netherlands) B.V. from EPIRUS Biopharmaceuticals, Inc..	30-06-16
Polpharma S.A. entered into a binding term sheet to acquire EPIRUS Biopharmaceuticals (Netherlands) B.V. from EPIRUS Biopharmaceuticals, Inc. for $3.5 million.	14-06-16
EPIRUS Biopharmaceuticals, Inc. Announces Executive Changes	09-05-16
EPIRUS Biopharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	29-03-16
EPIRUS Biopharmaceuticals, Inc. Announces Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2015	15-03-16
EPIRUS Biopharmaceuticals, Inc. Initiates Pivotal Global Phase 3 Clinical Study for BOW015 (Infliximab Biosimilar)	09-02-16
EPIRUS Biopharmaceuticals, Inc Provides Clinical Program Update on BOW015	16-11-15
EPIRUS Biopharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015	16-11-15
EPIRUS Biopharmaceuticals, Inc. Appoints Vincent E. Aurentz as Chief Business Officer	10-11-15

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Zalicus Inc Nasdaq

Aandelen

US98887C1053

Andere talen

Filters